Please ensure Javascript is enabled for purposes of website accessibility

Why Natus Medical Inc Sank Lower Today

By Brian Orelli, PhD - Jan 8, 2018 at 12:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

2017 ended with a bust, and it won't be a quick turnaround for the medical-device maker

What happened

Natus Medical (NTUS 1.41%) is down 15.6% at noon EST Monday after releasing disappointing 2017 preliminary revenue. Management also gave its 2018 guidance that suggests a slow recovery.

So what

Preliminary numbers for 2017 have revenue in the $500.5 million to $501.5 million range, substantially lower than the $514.5 million to $516.5 million that management guided for at the end of October. The problem seems to be mainly in Natus' U.S. neurodiagnostic business, although management didn't say why sales were weak. There was also a disruption from integrating its computer systems that resulted in lower sales of recently acquired Otometrics, which is presumably a one-time issue.

On the bright side, the recently acquired neurosurgery business was slightly above management's expectations, and revenue from newborn care was as expected.

Newborn and mother in a hospital bed

Image source: Getty Images.

Management didn't give preliminary earnings guidance, but presumably it'll fall below the adjusted earnings guidance of $1.72 to $1.76 per share that it gave in October.

Now what

Looking ahead, management expects revenue of $535.0 million to $540.0 million and adjusted earnings to fall in the range of $1.60 to $1.65 per share. At the midpoint, the revenue guidance is a 7.3% increase over the midpoint of preliminary 2017 revenue. That's not horrible growth, but keep in mind, it's coming off a lowered expectation.

And investors shouldn't expect a quick turnaround. For the first quarter of 2018, management expects revenue of $125.0 million to $127.0 million and adjusted earnings of $0.23 to $0.24 per share. Those numbers are well under one-fourth of the total expected for the year. The growth in the second half of the year will come from the expected release of Otoscan, a device that creates a computer image of the ear for fitting hearing aids.

If Natus can hit its 2018 numbers, it'll mean growth is again accelerating and today's price will look cheap, but investors are rightfully a little worried about whether management can hit its goals given its inability to hit the 2017 target.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Natus Medical Incorporated Stock Quote
Natus Medical Incorporated
$33.11 (1.41%) $0.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.